{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:37:21Z","timestamp":1790123841681,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41375-025-02845-7","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:22:25Z","timestamp":1767860545000},"page":"383-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-351X","authenticated-orcid":false,"given":"Fanny","family":"Gonzales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-6297","authenticated-orcid":false,"given":"Gabriela","family":"Alexe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7664-5030","authenticated-orcid":false,"given":"Allen","family":"Basanthakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana M.","family":"Ellegast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8858-2776","authenticated-orcid":false,"given":"Lucy","family":"Merickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvi","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Taillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8748-7012","authenticated-orcid":false,"given":"Mariateresa","family":"Giaimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Degar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-7895","authenticated-orcid":false,"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2845_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fped.2019.00463","volume":"7","author":"A Lonetti","year":"2019","unstructured":"Lonetti A, Pession A, Masetti R. Targeted therapies for pediatric AML: gaps and perspective. Front Pediatr. 2019;7:463.","journal-title":"Front Pediatr"},{"key":"2845_CR2","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1182\/blood.V97.12.3727","volume":"97","author":"UH Athale","year":"2001","unstructured":"Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution\u2019s experience. Blood. 2001;97:3727\u201332.","journal-title":"Blood"},{"key":"2845_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/pbc.20951","volume":"49","author":"DR Barnard","year":"2007","unstructured":"Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG. Children\u2019s Oncology Group. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2007;49:17\u201322.","journal-title":"Pediatr Blood Cancer"},{"key":"2845_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2012.10.007","volume":"22","author":"Gruber TA","year":"2012","unstructured":"Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22:683\u201397.","journal-title":"Cancer Cell"},{"key":"2845_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2017.02.006","volume":"31","author":"C Thirant","year":"2017","unstructured":"Thirant C, Ignacimouttou C, Lopez CK, Diop M, Le Mou\u00ebl L, Thiollier C, et al. ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and self-renewal in pediatric acute megakaryoblastic leukemia. Cancer Cell. 2017;31:452\u201365.","journal-title":"Cancer Cell"},{"key":"2845_CR6","doi-asserted-by":"crossref","unstructured":"Bertuccio SN, Boudia F, Cambot M, Lopez CK, Lordier L, Donada A, et al. The pediatric acute leukemia fusion oncogene ETO2-GLIS2 increases self-renewal and alters differentiation in a human induced pluripotent stem cells-derived model. HemaSphere. 2019;4:e319.","DOI":"10.1097\/HS9.0000000000000319"},{"key":"2845_CR7","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/2159-8290.CD-18-1463","volume":"9","author":"CK Lopez","year":"2019","unstructured":"Lopez CK, Noguera E, Stavropoulou V, Robert E, Aid Z, Ballerini P, et al. Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia. Cancer Discov. 2019;9:1736\u201353.","journal-title":"Cancer Discov"},{"key":"2845_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ng.3772","volume":"49","author":"JDE de Rooij","year":"2017","unstructured":"de Rooij JDE, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al. Pediatric non-down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017;49:451\u20136.","journal-title":"Nat Genet"},{"key":"2845_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bjh.15725","volume":"184","author":"R Masetti","year":"2019","unstructured":"Masetti R, Bertuccio SN, Pession A, Locatelli F. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol. 2019;184:337\u201347.","journal-title":"Br J Haematol"},{"key":"2845_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","volume":"26","author":"JL Smith","year":"2020","unstructured":"Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, et al. Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options \u2013 a COG and TARGET pediatric AML study. Clin Cancer Res J Am Assoc Cancer Res. 2020;26:726\u201337.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"2845_CR11","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","volume":"12","author":"JM Ellegast","year":"2022","unstructured":"Ellegast JM, Alexe G, Hamze A, Lin S, Uckelmann HJ, Rauch PJ, et al. Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts. Cancer Discov. 2022;12:1760\u201381.","journal-title":"Cancer Discov"},{"key":"2845_CR12","doi-asserted-by":"crossref","unstructured":"Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2021;candisc.1851.2020.","DOI":"10.1101\/2020.12.28.424340"},{"key":"2845_CR13","doi-asserted-by":"crossref","unstructured":"Wunderlich M, Chen J, Sexton C, Manning N, Byerly L, O\u2019Brien E, et al. PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets. bioRxiv. 2022. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.01.31.478534v1.full.","DOI":"10.1101\/2022.01.31.478534"},{"key":"2845_CR14","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1093\/nar\/gku936","volume":"42","author":"EK Brinkman","year":"2014","unstructured":"Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014;42:e168.","journal-title":"Nucleic Acids Res"},{"key":"2845_CR15","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/blood-2014-01-547760","volume":"123","author":"N Bhagwat","year":"2014","unstructured":"Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 2014;123:2075\u201383.","journal-title":"Blood"},{"key":"2845_CR16","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779\u201384.","journal-title":"Nat Genet"},{"key":"2845_CR17","unstructured":"DepMap: The Cancer Dependency Map Project at Broad Institute. 2025. Available from: https:\/\/depmap.org\/portal\/."},{"key":"2845_CR18","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","volume":"10","author":"BJ Aubrey","year":"2015","unstructured":"Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O\u2019Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10:1422\u201332.","journal-title":"Cell Rep"},{"key":"2845_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1158\/0008-5472.CAN-22-2245","volume":"83","author":"KR Hagel","year":"2023","unstructured":"Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, et al. Systematic interrogation of tumor cell resistance to chimeric antigen receptor T-cell therapy in pancreatic cancer. Cancer Res. 2023;83:613\u201325.","journal-title":"Cancer Res"},{"key":"2845_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"key":"2845_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm Rev. 2006;58:621\u201381.","journal-title":"Pharm Rev"},{"key":"2845_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"2845_CR23","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","volume":"50","author":"AD Durbin","year":"2018","unstructured":"Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018;50:1240\u20136.","journal-title":"Nat Genet"},{"key":"2845_CR24","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1172\/JCI90793","volume":"128","author":"L Chen","year":"2018","unstructured":"Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018;128:446\u201362.","journal-title":"J Clin Invest"},{"key":"2845_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41588-021-00819-w","volume":"53","author":"NV Dharia","year":"2021","unstructured":"Dharia NV, Kugener G, Guenther LM, Malone CF, Durbin AD, Hong AL, et al. A first-generation pediatric cancer dependency map. Nat Genet. 2021;53:529\u201338.","journal-title":"Nat Genet"},{"key":"2845_CR26","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","volume":"123","author":"R Rampal","year":"2014","unstructured":"Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123\u201333.","journal-title":"Blood"},{"key":"2845_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013;161:508\u201316.","journal-title":"Br J Haematol"},{"key":"2845_CR28","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Ostojic, Vrhovac, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag. 2012;95:95\u2013103.","DOI":"10.2147\/TCRM.S23277"},{"key":"2845_CR29","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020;25:e328\u201334.","journal-title":"Oncologist"},{"key":"2845_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","volume":"28","author":"SC Meyer","year":"2015","unstructured":"Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms. Cancer Cell. 2015;28:15\u201328.","journal-title":"Cancer Cell"},{"key":"2845_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","volume":"28","author":"SC Wu","year":"2015","unstructured":"Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, et al. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. Cancer Cell. 2015;28:29\u201341.","journal-title":"Cancer Cell"},{"key":"2845_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aat3834","volume":"4","author":"D Tvorogov","year":"2018","unstructured":"Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Sci Adv. 2018;4:eaat3834.","journal-title":"Sci Adv"},{"key":"2845_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","volume":"2","author":"R Andraos","year":"2012","unstructured":"Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, et al. Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. Cancer Discov. 2012;2:512\u201323.","journal-title":"Cancer Discov"},{"key":"2845_CR34","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1038\/leu.2016.119","volume":"30","author":"LE Brodersen","year":"2016","unstructured":"Brodersen LE, Alonzo T, Menssen A, Gerbing R, Pardo L, Voigt A, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children\u2019s Oncology Group. Leukemia. 2016;30:2077\u201380.","journal-title":"Leukemia"},{"key":"2845_CR35","doi-asserted-by":"publisher","first-page":"6117","DOI":"10.1182\/blood-2022-164699","volume":"140","author":"SK Tasian","year":"2022","unstructured":"Tasian SK, Hunter DS, Chen IML, Harvey RC, Carroll AJ, Wagner E, et al. A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (AALL1521\/INCB18424-269): biologic characteristics and minimal residual disease response of patients with non-CRLF2-rearranged JAK pathway alterations. Blood. 2022;140:6117\u20138.","journal-title":"Blood"},{"key":"2845_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184\u201391.","journal-title":"Nat Biotechnol"},{"key":"2845_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u20137.","journal-title":"Science"},{"key":"2845_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther"},{"key":"2845_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","volume":"15","author":"F Seif","year":"2017","unstructured":"Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal CCS. 2017;15:23.","journal-title":"Cell Commun Signal CCS"},{"key":"2845_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18925-4","volume":"11","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J, Castro CN, Tusseau M, Stolzenberg MC, Mazerolles F, Aladjidi N, et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun. 2020;11:5341.","journal-title":"Nat Commun"},{"key":"2845_CR41","doi-asserted-by":"publisher","first-page":"6405","DOI":"10.3892\/mmr.2017.7384","volume":"16","author":"YB Liang","year":"2017","unstructured":"Liang YB, Tang H, Chen ZB, Zeng LJ, Wu JG, Yang W, et al. Downregulated SOCS1 expression activates the JAK1\/STAT1 pathway and promotes polarization of macrophages into M1 type. Mol Med Rep. 2017;16:6405\u201311.","journal-title":"Mol Med Rep"},{"key":"2845_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40142-016-0100-7","volume":"4","author":"WE Tidyman","year":"2016","unstructured":"Tidyman WE, Rauen KA. Expansion of the RASopathies. Curr Genet Med Rep. 2016;4:57\u201364.","journal-title":"Curr Genet Med Rep"},{"key":"2845_CR43","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/ng.3427","volume":"47","author":"R Arafeh","year":"2015","unstructured":"Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, et al. Recurrent inactivating RASA2 mutations in melanoma. Nat Genet. 2015;47:1408\u201310.","journal-title":"Nat Genet"},{"key":"2845_CR44","doi-asserted-by":"publisher","first-page":"11473","DOI":"10.1073\/pnas.1324128111","volume":"111","author":"PC Chen","year":"2014","unstructured":"Chen PC, Yin J, Yu HW, Yuan T, Fernandez M, Yung CK, et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc Natl Acad Sci USA. 2014;111:11473\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2845_CR45","doi-asserted-by":"crossref","unstructured":"Drenberg CD, Shelat A, Dang J, Cotton A, Orwick SJ, Li M, et al. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nat Commun. 2019;10:2189.","DOI":"10.1038\/s41467-019-09917-0"},{"key":"2845_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"2845_CR47","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371:1005\u201315.","journal-title":"N Engl J Med"},{"key":"2845_CR48","doi-asserted-by":"publisher","first-page":"89923","DOI":"10.18632\/oncotarget.21027","volume":"8","author":"EMP Steeghs","year":"2017","unstructured":"Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, et al. JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia. Oncotarget. 2017;8:89923\u201338.","journal-title":"Oncotarget"},{"key":"2845_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673\u201383.","journal-title":"Nat Rev Cancer"},{"key":"2845_CR50","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2159-8290.CD-22-0952","volume":"14","author":"AJ Dunbar","year":"2024","unstructured":"Dunbar AJ, Bowman RL, Park YC, O\u2019Connor K, Izzo F, Myers RM, et al. Jak2V617F reversible activation shows its essential requirement in myeloproliferative neoplasms. Cancer Discov. 2024;14:737\u201351.","journal-title":"Cancer Discov"},{"key":"2845_CR51","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/pbc.25575","volume":"62","author":"ML Loh","year":"2015","unstructured":"Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children\u2019s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62:1717\u201324.","journal-title":"Pediatr Blood Cancer"},{"key":"2845_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNLde, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review. Clin Pharmacokinet. 2023;62:559\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"2845_CR53","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1097\/HS9.0000000000000562","volume":"5","author":"CN Harrison","year":"2021","unstructured":"Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, et al. Fedratinib improves myelofibrosis-related symptoms and health-related quality of life in patients with myelofibrosis previously treated with ruxolitinib: patient-reported outcomes from the phase II JAKARTA2 trial. HemaSphere. 2021;5:e562.","journal-title":"HemaSphere"},{"key":"2845_CR54","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood.2023022565","volume":"144","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland F, Faraci M, et al. Ruxolitinib for pediatric patients with treatment-na\u00efve and steroid-refractory acute graft-versus-host disease: the REACH4 study. Blood. 2024;144:2095\u2013106.","journal-title":"Blood"},{"key":"2845_CR55","doi-asserted-by":"publisher","first-page":"3147.1","DOI":"10.1182\/blood-2024-193905","volume":"144","author":"JO Mascarenhas","year":"2024","unstructured":"Mascarenhas JO, Borate U, Bose P, Byrd JC, Garcia JS, Grunwald MR, et al. A multicenter, open-label, phase 1 clinical trial of AJ1-11095 administered as oral monotherapy in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have been failed by a type I JAK2 inhibitor (JAK2i). Blood. 2024;144:3147.1.","journal-title":"Blood"},{"key":"2845_CR56","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/1078-0432.CCR-23-0163","volume":"30","author":"T Codilupi","year":"2024","unstructured":"Codilupi T, Szybinski J, Arunasalam S, Jungius S, Dunbar AC, Stivala S, et al. Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clin Cancer Res J Am Assoc Cancer Res. 2024;30:586\u201399.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"2845_CR57","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI98785","volume":"129","author":"S Stivala","year":"2019","unstructured":"Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, et al. Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;129:1596\u2013611.","journal-title":"J Clin Invest"},{"key":"2845_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60884-1","volume":"16","author":"N Maslah","year":"2025","unstructured":"Maslah N, Kaci N, Roux B, Alexe G, Marie R, Pasquer H, et al. JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. Nat Commun. 2025;16:6270.","journal-title":"Nat Commun"},{"key":"2845_CR59","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26731","volume":"97","author":"D Rivera","year":"2022","unstructured":"Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, et al. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022;97:1599\u2013606.","journal-title":"Am J Hematol"},{"key":"2845_CR60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-19-0209","volume":"10","author":"A Cremer","year":"2020","unstructured":"Cremer A, Ellegast JM, Alexe G, Frank ES, Ross L, Chu SH, et al. Resistance mechanisms to SYK inhibition in acute myeloid leukemia. Cancer Discov. 2020;10:214\u201331.","journal-title":"Cancer Discov"},{"key":"2845_CR61","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/bloodadvances.2020003398","volume":"5","author":"CAC Peretz","year":"2021","unstructured":"Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, et al. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood Adv. 2021;5:1437.","journal-title":"Blood Adv"},{"key":"2845_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","volume":"2","author":"AS Alotaibi","year":"2021","unstructured":"Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021;2:125\u201334.","journal-title":"Blood Cancer Discov"},{"key":"2845_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00687-5","volume":"12","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022;12:91.","journal-title":"Blood Cancer J"},{"key":"2845_CR64","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","volume":"124","author":"MR Burgess","year":"2014","unstructured":"Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, et al. Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood. 2014;124:3947\u201355.","journal-title":"Blood"},{"key":"2845_CR65","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AMC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401:733\u201346.","journal-title":"Lancet"},{"key":"2845_CR66","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non\u2013small-cell lung cancer: 2-year analysis of CodeBreaK 100. J Clin Oncol. 2023;41:3311\u20137.","journal-title":"J Clin Oncol"},{"key":"2845_CR67","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2021.39.15_suppl.3007","volume":"39","author":"SJ Shin","year":"2021","unstructured":"Shin SJ, Lee J, Kim TM, Kim JS, Kim YJ, Hong YS, et al. A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion. J Clin Oncol. 2021;39:3007\u20133007.","journal-title":"J Clin Oncol"},{"key":"2845_CR68","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1172\/JCI74182","volume":"124","author":"G Kong","year":"2014","unstructured":"Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest. 2014;124:2762\u201373.","journal-title":"J Clin Invest"},{"key":"2845_CR69","doi-asserted-by":"publisher","first-page":"5933","DOI":"10.1182\/bloodadvances.2022008503","volume":"6","author":"T Tang","year":"2022","unstructured":"Tang T, Le Q, Castro S, Pardo L, McKay CN, Perkins L, et al. Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1\u2013antibody-drug conjugate. Blood Adv. 2022;6:5933\u20137.","journal-title":"Blood Adv"},{"key":"2845_CR70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157101","volume":"132","author":"Q Le","year":"2022","unstructured":"Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, et al. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. J Clin Invest. 2022;132:e157101.","journal-title":"J Clin Invest"},{"key":"2845_CR71","doi-asserted-by":"crossref","unstructured":"Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, et al. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. J Clin Invest. 2024;134:e157101.","DOI":"10.1172\/JCI184305"},{"key":"2845_CR72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","volume":"595","author":"N Xu","year":"2022","unstructured":"Xu N, Yang XF, Xue SL, Tan JW, Li MH, Ye J, et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochem Biophys Res Commun. 2022;595:54\u201361.","journal-title":"Biochem Biophys Res Commun"},{"key":"2845_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00262-024-03927-8","volume":"74","author":"K Mitsuno","year":"2025","unstructured":"Mitsuno K, Suematsu M, Naito Y, Mayumi A, Yoshida H, Osone S, et al. Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer Immunol Immunother CII. 2025;74:79.","journal-title":"Cancer Immunol Immunother CII"},{"key":"2845_CR74","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.3324\/haematol.2022.282637","volume":"108","author":"LM Niswander","year":"2023","unstructured":"Niswander LM, Chung P, Diorio C, Tasian SK. Clinical responses in pediatric patients with relapsed\/refractory leukemia treated with azacitidine and venetoclax. Haematologica. 2023;108:3142\u20137.","journal-title":"Haematologica"},{"key":"2845_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/bloodadvances.2022008899","volume":"8","author":"V Gress","year":"2024","unstructured":"Gress V, Roussy M, Boulianne L, Bilodeau M, Cardin S, El-Hachem N, et al. CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216. Blood Adv. 2024;8:112\u201329.","journal-title":"Blood Adv"},{"key":"2845_CR76","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41375-022-01800-0","volume":"37","author":"Z Aid","year":"2023","unstructured":"Aid Z, Robert E, Lopez CK, Bourgoin M, Boudia F, Le Mene M, et al. High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia. Leukemia. 2023;37:571\u20139.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02845-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:03:37Z","timestamp":1770278617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02845-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02845-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6528748\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FG was supported with funding from the French National Cancer Institute and the ARC Foundation for Cancer Research. CS was supported by a Helen Gurley Brown Fellowship. CS and KS were supported with funding from The Selig Family Fund for Pediatric Cancer Research. JME received funding from the Rally Foundation for Childhood Cancer Research and the American Society of Hematology. SL was a Fellow of Blood Cancer United, formerly The Leukemia & Lymphoma Society and was supported by NCI R00 CA263161. MW was supported by NCI R50 CA211404. YP received support from CURE Childhood Cancer Foundation, Rally Foundation for Childhood Cancer Research, St. Baldrick\u2019s Foundation and Hyundai Hope on Wheels. KS was supported by Blood Cancer United, formerly The Leukemia & Lymphoma Society, Rally Foundation for Childhood Cancer Research, Children\u2019s Leukemia Research Association (CLRA), and a National Cancer Institute R35 CA283977. KS received grant funding from the DFCI\/Novartis Drug Discovery Program and is a member of the SAB and has stock options with Auron Therapeutics on topics unrelated to this work. JME reports spousal employment at Novartis Pharma AG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. All animal experiments were approved by the DFCI Institutional Animal Care and Use Committee and conducted in accordance with institutional guidelines. Informed consent was obtained from all participants or their legal guardians prior to sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}